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Increasing hepatic arterial flow to hypovascular hepatic tumours using
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Summary The effect of degradable starch microspheres (DSM) on the intrahepatic distribution of a low
molecular weight marker, "9Tcm-labelled methylene diphosphonate (MDP), was studied in rats with
hypovascular HSN liver tumours. MDP was injected regionally, via the hepatic artery, alone or co-
administered with DSM, with or without subsequent occlusion of either the hepatic artery or the portal vein.
Tumour vascularity was measured with 57Co-labelled microspheres. Co-injection with DSM immediately
significantly increased hepatic retention of marker in both tumour (T) (median 22.40 (range 16.82-39.58)%
injected dose) and normal liver (N) (9.08 (4.85-12.59) %ID) the greater effect seen in T (P<0.01). After DSM
degradation, very little MDP remained in N (0.61 (0.28-1.40) %ID) but there was significant retention in T
(10.01 (6.73-20.28) %ID, P<0.01). Clamping the hepatic artery had minimal effect on the retention of MDP
when administered alone. Regional injection of 16.5 gm "Co microspheres resulted in a N:T ratio of 2.25:1.
Concomitant injection of the 40 gm DSM with 57Co microspheres reversed this ratio to 1:2. The results
indicate that DSM selectively enhances the retention of MDP to a hypovascular hepatic tumour, not by
causing intra-tumour stasis, but by directing a greater arterial flow to hypovascular areas in the liver.
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Although tumour cells may metastasise to the liver via the
portal vein (Fisher and Turnbull, 1955), as they grow and
develop their blood supply is derived principally from the
hepatic artery (Healy, 1965; Ackerman, 1974). In contrast,
the liver parenchyma has a dual blood supply from the
hepatic artery and portal vein which provide 30% and 70%
of the total liver blood flow. Regional chemotherapy, that is
the administration of cytotoxic drugs via the hepatic artery,
aims to exploit this difference in the blood supply to normal
liver and tumour by the selective perfusion of the metastatic
deposits (Ensminger and Gyves, 1983).
Prospective trials of regional chemotherapy for hepatic
metastases have shown improved response rates compared
with systemic administration of the same drugs (Neiderhuber
et al., 1984) but survival is not significantly prolonged
(Schwartz et al., 1985). Failure to substantially affect the
natural history of the disease may be partially explained by
the hypovascularity of many of the metastatic tumours.
Theoretically, regional infusions of a chemotherapeutic agent
will only increase drug concentrations to hypervascular areas
in the liver. Clearly, therefore, administering a cytotoxic drug
via the hepatic artery is inadequate to achieve a high tumour
kill in hypovascular metastases and additional manipulation
of the intrahepatic blood flow is required to improve drug
delivery to the tumour. A variety of methods have been
employed to alter blood flow to liver metastases. One such
technique involves the use of degradable starch microspheres
(DSM, Spherex, Pharmacia, Sweden) to induce temporary
arterial embolisation. These microspheres, which have a mean
diameter of 40 gm, consist of starch polymers cross-linked
with epichlorhydrine. They are degraded by endogenous
serum alpha-amylases and have a half-life in human serum of
25 min at 37°C in vitro. After regional administration via the
hepatic artery the microspheres lodge in the small arterioles
thereby slowing arterial inflow and resulting in intrahepatic
arterial stasis. Regionally delivered cytotoxic drugs adminis-
tered concomitantly with DSM are retained within the liver
considerably longer than when the drugs are given alone
(Lindell et al., 1978; Lorelius et al., 1984; Teder et al., 1986).
Furthermore, DSM preferentially enhances the delivery of
drug to hepatic tumour (Chang et al., 1989). However, it is
unclear how these biodegradable emboli produce this effect.
Therefore the aim of this study was to elucidate the
underlying mechanisms of action of DSM in altering the
intrahepatic distribution of a low molecular weight marker
representing a cytotoxic drug. The experiments were designed
to simulate as closely as possible the regional chemotherapy
treatment of patients with colorectal liver metastases.
Materials and methods
Liver tumour model
Liver tumours were established in hooded Lister rats (200-
250 g body weight) by intraportal inoculation of a single-cell
suspension of 5 x 105 HSN fibrosarcoma cells. This is a
syngeneic cell-line grown from tissue culture. The rats were
studied 21 days after administration of the tumorigenic cells
when 4-8 discrete tumour nodules with a mean diameter of
7.5 mm were present in the liver of all the animals.
Tumour vascularity
The vascularity of HSN sarcoma-derived tumour relative to
the normal liver parenchyma was determined by histological
examination and by the intrahepatic distribution of small
radiolabelled, non-degradable "Co microspheres, 16.5 gm in
diameter (Nen-Trac, New England Nuclear, Stevenage, UK).
After regional injection via the hepatic artery (n= 11) or
portal vein (n=9), these microspheres follow the paths of
greatest flow and ultimately lodge at the intrahepatic
presinusoidal level. Each injectate contained 40 000 micro-
spheres which provided at least 400 microspheres per liver
tissue sample, thereby minimising statistical errors (Buckberg
et al., 1971). In brief, 5 min after injection of the micro-
spheres the rats were killed, the livers excised and divided
into normal liver and tumour areas and the radioactivity of
each section of liver measured in a gamma-well counter (1280
Ultragamma, LKB Wallac, UK). A schematic picture of the
intrahepatic distribution of the microspheres was then built
up and the ratio between tumour and normal liver tissue
calculated.
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Degradable starch microspheres
The serum amylase concentration of normal rats (range of
1000- 1500 Ul-) is much higher than in man, and hence the
starch microspheres used in human studies are degraded
within seconds after intravascular administration in the rat.
Therefore for our experiments microspheres were developed
containing a greater number of cross-linkages (batch pH BR
58B43B 93769a), and a degradation time in the rat similar
to that of human microspheres in man, i.e. a half-life of
25 min.
Optimising the dose of DSM
We have previously described a method for determining the
optimal dose of starch microspheres to retain a low molecular
weight marker within the liver using the Spherex monitoring
system in a normal rat (Nott et al., 1987). Applying the same
technique to rats with hepatic tumours derived from HSN
sarcoma cells we found that the dose of DSM which retained
the maximum quantity of MDP within the liver without
causing overspillage of microspheres into the splanchnic
circulation was 2 mg.
Low molecular weight marker
The low molecular weight marker chosen for these
experiments was 99Tcm-labelled methylene diphosphonate
(MDP). This marker is extensively used for bone scans and
is not normally retained nor metabolised to any significant
degree by the liver. However, MDP is of a similar size to
commonly used cytotoxic drugs and is readily radiolabelled
and counted. It has the additional advantages of rapid
equilibration throughout the body, relative inexpense and is
convenient to use.
Procedures
In all experiments the animals, fasted overnight but allowed
access to water ad libitum, were anaesthetised with sodium
pentobarbital (60 mg per kg body weight). Through a midline
incision a 2 Fr Portex cannula was placed in the
gastroduodenal artery such that its tip lay at the junction
with the common hepatic artery. All subsequent injections
given via this cannula were observed under direct vision using
an operating microscope to ensure that the injection pressures
did not produce backfiow down the coeliac artery and hence
into the splanchnic circulation. Blood pressure and heart rate
were monitored continuously during each experiment by a
pressure transducer (Medox Medical, Rossendale, UK)
attached to a cannula placed in the left femoral artery. The
volume of each injectate did not exceed 0.05 ml, this being
the approximate arterial volume of the rat liver (Chang,
1993), and was administered using a high pressure liquid
chromatography (HPLC) syringe. The low molecular weight
marker (MDP) or 57Co microspheres and DSM were
thoroughly mixed with the aid of a vortex mixer immediately
before administration.
Control group
A control group of 20 rats received a regional injection, via
the hepatic artery, of MDP alone and the animals were killed,
1 min (n= 10) and 90 min (n= 10) later.
Experimental groups
In the first experimental group of 20 rats, MDP was co-
injected with rat DSM (2 mg) via the hepatic artery. Ten
animals were killed 1 min after injection and the remainder
90 min later. To compare the starch microspheres used in
clinical studies a second group of 8 rats were given 2 mg of
human DSM with MDP and killed after 90 min.
In the third series of experiments the hepatic artery or
portal vein were occluded either before or after regional
administration of the low molecular weight marker. In a
group of eight rats immediately after injection of MDP the
hepatic artery was clamped for 90 min and the animals then
killed. In the next group of 16 rats the portal vein was
clamped immediately before receiving an injection of MDP
together with DSM. Eight rats were killed 1 min after
injection, while in the other eight the clamp was removed
after 1 min but the animals not killed for a further 90 min.
Freshly prepared MDP (30 jug mCi-1, with an activity
ranging from 40 to 60 MBq ml-') and DSM (100 mg ml-')
were used in each experiment. In all rats the livers were
immediately excised and divided into normal liver and tumour
areas resulting in 100-150 samples. Each sample, weighing
between 100 and 250 mg, was placed at the bottom of a plastic
vial and the radioactivity counted in a gamma-well counter. A
schematic picture of MDP distribution in tumour and normal
livertissuecouldthenbeconstructed. Theactivityoftheinjected
dose ofmarker was determined by withdrawing and counting a
volume equal to that injected in each experiment from the stock
solution ofMDP. In this way theconcentration ofmarkerin the
tissues could be calculated in terms ofpercentage oftheinjected
dose per milligram ofthe wet weight tissue (%ID per mg). The
percentage ofmarker retained in tumour or liver for each group
was calculated from the product of the total tissue weight and
concentration ofmarker per mg oftissue.
A final group of 11 rats received co-injections of 57Co
microspheres and 2 mg of DSM, via the hepatic artery, to
examine the effect of the starch microspheres on the
intrahepatic distribution of the much smaller non-degradable
microspheres. These animals were killed 5 min after injection,
the livers excised and the activity counted in tumour and
normal liver as previously described.
Statistical analysis
Results were analysed using non-parametric statistical
methods. The Mann-Whitney U-test was used to assess
significant differences between groups.
Results
Tumour vascularity
For each group the mean weight of the tumours ranged from
20% to 26% of the total liver weight. Microscopic
examination revealed irregularly shaped and densely packed
cells with few vessels coursing through the tumour. The
relatively hypovascular nature of this tumour was confirmed
by the distribution of the 57Co microspheres. Thus, following
regional intra-arterial injection of "7Co a greater number of
microspheres was found in normal liver parenchyma than in
tumour tissue resulting in a liver to tumour ratio of 2.25:1
(Table I). In addition, measurement of the lung counts
demonstrated no significant arteriovenous shunting. Very few
Table I Intrahepatic radioactivity, median (range), after regional injection of 57Co microspheres via the hepatic artery
(HA) or portal vein (PV)
Tissue radioactivity
(cps mg 1 tissue x 10-) % arterio
Normal liver Tumour N:T venous
No. (N) (T) ratio shunt
HA 11 9.64 (4,92-13.01) 4.28 (2.60-8.11) 2.25: 1 0.19
PV 9 9.50 (2.16-16.47) 0.12 (0.03-0.44) 79.17: 1 1.15Increasing hepatic arterial flow
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microspheres reached the tumour from the portal circulation
with 80 times more in normal liver compared with tumour
tissue (Table I). Therefore, although the main blood supply
to this tumour was from the hepatic artery the tumour blood
flow was half that to the liver parenchyma.
Intrahepatic marker distribution
Figure 1 shows that 1 min after the intra-arterial injection of
MDP alone there was a small but significantly (P<0.02)
greater retention of marker in tumour [5.32% (2.74-6.72) of
the injected dose per mg of tissue, median and range]
compared with normal liver tissue (3.69, range 2.40-4.82).
However, 1 min after the concomitant administration of
DSM with MDP the retention of the marker within the liver
was significantly increased compared to injection of marker
alone (P<0.001) such that the total amount of marker
retained in the liver increased from 5.81% to 23.76%.
Moreover, the greatest concentration of MDP was found in
tumour tissue (22.40, range 16.82-39.58) compared with
normal liver parenchyma (9.08, range 4.85-12.59; P<0.001).
Ninety minutes after regional administration of the MDP
the marker had equilibrated throughout the rat's body. In the
control group of rats receiving MDP alone very little marker
remained in the liver (1.27%) and there was no significant
difference in the concentrations between tumour (0.77, range
0.55-1.43) and normal liver tissue (0.53, range 0.27-1.19).
Co-injection of DSM with MDP did not affect the
concentration of marker retained in normal liver tissue
(0.61, range 0.28-1.40). In contrast 13 times more MDP
was found in tumour (10.01, range 6.73-20.28; P<0.001)
compared with that in the liver tumours of the control group
despite the fact that at this stage over 95% of the starch
microspheres had degraded. The total amount of marker
retained within the liver was increased over five-fold to
7.12% of the injected dose.
A similar result was observed after 90 min when using the
human DSM in the rat despite the more rapid degradation of
these microspheres (Figure 2). In contrast, mechanical
occlusion of the hepatic artery with a clamp had minimal
effect on retention (1.54%) and intrahepatic distribution of
the low molecular weight marker and there was no significant
difference compared with the control group.
Effects ofportal venous occlusion
The effects of manipulating portal venous inflow on the
intrahepatic distribution of marker after co-injection with
DSM are summarised in Figure 3. Occlusion ofthe portal vein
produced intrahepatic venous stasis and increased the
concentration of MDP in the liver. This effect was more
pronounced in normal liver tissue (27.65, range 11.98-48.29),
compared with tumour (8.65, range 5.72- 17.99; P<0.001).
Following the release of the venous clamp there was a
significant reduction in these concentrations though by
differing amounts for normal and tumour tissue. There was
an 18-fold loss ofmarker from normal liver (1.56, range 0.51 -
4.36) compared with a 2-fold reduction in tumour (4.23, range
2.23-9.81; P<0.001). The total intrahepatic MDP concentra-
tion at 90 min was reduced to 4.64% compared with 7.12%
during normal venous inflow largely as a result of the lower
intratumour concentration. The concentration of marker
washout from tumour and normal liver remained constant in
all groups being 49% from tumour and 91% from liver tissue.
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Figure 1 Concentration of MDP in the liver 1 min after regional
injection of MDP alone or with DSM. Bars are medians.
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Figure 2 Concentration of MDP in the liver 90min after
regional injection of MDP alone, MDP and DSM, MDP and
human DSM, and MDP alone but with the hepatic artery
occluded. Bars are medians.
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Figure 3 Concentration of MDP in the liver after regional
injection of MDP and DSM but with the portal vein occluded for
1 min. Bars are medians.
Discussion
DSM and 57Co microspheres
In the final experiment regional injection of DSM with 57Co
microspheres significantly altered the intrahepatic distribution
pattern of the smaller radiolabelled microspheres. Compared
with administration of the 57Co microspheres alone the ratio
of tumour to normal liver tissue was completely reversed
(Figure 4). Furthermore, there was no change in the degree of
arteriosystemic shunting.
Since the majority of liver metastases in man are isovascular
or hypovascular (Healey, 1965; Kim et al., 1977; Lin et al.,
1984), we developed an easily reproducible tumour model in
the rat that reflects these characteristics. Direct observation
of all the injections using an operating microscope allowed
for the careful control of the animal's physiological
parameters. Furthermore, by using DSM designed to
degrade at the same rate as in man a more direct comparison
can be made with clinical studies. Previously published
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Figure 4 Intrahepatic distribution of 57Co microspheres after
regional injection alone or with 2mg of DSM. Bars are medians.
animal work using these microspheres has not taken these
factors into consideration.
In the control group of rats, given MDP alone via the
hepatic artery, more marker initially accumulated in tumour
than in the normal liver parenchyma. This was surprising in
view of the comparatively poor arterial supply to the tumour
but could result from different partition coefficients for the
marker between the two tissues. However, substances injected
into the hepatic artery can pass, via terminations of the
arterial vessels into the portal vein and hepatic sinusoids
(Rappaport, 1973; McCuskey, 1966), to the systemic
circulation. Drugs and compounds like MDP which are not
actively extracted by the liver will be washed out of the liver
by this route with the portal venous inflow influencing the
rate and volume of the washout. Thus the portal inflow may
have rapidly washed out the marker from the normal liver
but not from the tumour which has a poor portal venous
supply. This is supported by the fact that 90 min after
administration of MDP, when the marker has had sufficient
time to equilibriate in the rat's body, there was no difference
between the concentration of marker retained in normal liver
and tumour.
Addition of DSM to the regional injectate of MDP
immediately increased the intrahepatic concentration of
marker. This initial increase in marker retention was
expected from the DSM-induced vascular blockade and
observed directly with the operating microscope. An
unexpected finding was the selective localisation of MDP to
the tumour. Two possible explanations may account for this
phenomenon. First, since portal venous flow is unaffected by
DSM arterial embolisation, less marker remains in normal
liver than tumour owing to the portal venous washout,
nullifying any stasis induced downstream to the DSM.
Second, co-injection with DSM preferentially targets marker
to tumour. The 3-fold difference in marker distribution
between tumour and liver after concomitant administration
with DSM suggests additional factors to portal washout are
responsible for this effect. One such possibility is that DSM
increases arterial blood flow to tumour thereby facilitating
selective delivery of the marker.
When injected into the circulation microspheres tend to
follow high flow pathways (Yipintsoi et al., 1973). Thus, the
greatest degree of embolisation and hence marker entrap-
ment, should occur within normal liver rather than the
hypovascular HSN tumour. Paradoxically, in this study more
MDP was retained within the tumour, and therefore the
difference in the intrahepatic marker distribution cannot be
explained merely on the basis of prolonged intra-arterial
embolisation of DSM and sequestration of MDP. Further-
more, arterial stasis after clamping the hepatic artery per se
did not significantly affect marker distribution. Therefore, in
addition to producing intrahepatic arterial stasis DSM must
alter intrahepatic blood flow thereby targeting the marker to
tumour. Two factors indicate this was an immediate effect.
First, the changes in marker distribution after injection of
MDP with DSM were observed within the first minute.
Second, co-administration of marker with human DSM,
which are rapidly degraded in rats, resulted in a similar
intrahepatic distribution of MDP at 90 min as that observed
with the specifically designed rat DSM. Moreover, this
accounts for the results of previous studies which have
reported increased drug concentrations in experimental
tumour 5 min (Flowerdew et al., 1987) or 30 min
(Sigurdson et al., 1986) after co-injection with human DSM.
In the present study, 90 min after regional injection of
MDP and DSM, when over 95% of the starch microspheres
had degraded, the concentration of marker retained in
normal liver was comparable with the control group
receiving MDP alone. In contrast 13 times more MDP
remained in tumour compared with the control group. Thus
the disparity in marker distribution was not only maintained
after DSM degradation but was amplified, possibly owing to
a combined effect of DSM-induced tumour arterial stasis and
relatively poor portal washout of marker from tumour.
As expected, reduction of the portal venous inflow by
occlusion of the portal vein further increases the concentra-
tion of marker within the liver. However, despite the presence
of DSM, relatively more marker was now localised in normal
liver and less in tumour compared with the group whose
portal flow was uninterrupted, even after restoration ofportal
flow and degradation of the DSM. It is known that a
reduction in portal venous flow leads to a compensatory
increase in hepatic arterial flow (Greenway and Oshiro,
1972). Furthermore, Ackerman et al. (1972) reported that
acute ligation of the portal vein in rats with overt liver
tumours diverts blood flow from tumour to liver. They
suggested that this was caused either by better arterial
perfusion to liver than to tumour or the shunting of arterial
blood to the intrahepatic portal circulation. In the present
study the increase in hepatic arterial flow secondary to the
reduced portal venous flow in animals with HSN tumour will
be proportionally greater in normal liver than the less
vascular tumour, which may account for the relatively
greater accumulation of DSM and co-injected marker in
liver tissue. These results provide further evidence that the
intrahepatic vascular flow pattern largely determines the
distribution of the DSM. In addition, the results suggest that
interference with the portal blood flow will have a deleterious
therapeutic effect on intra-arterially injected cytotoxic drugs
given with DSM.
The results from the final part of this study clearly indicate
that when regionally co-injected with DSM, significantly
more of the radiolabelled 57Co microspheres were entrapped
in tumour compared with the normal liver. The reversed
tumour to liver ratio for 57Co activity after injection with
DSM suggests a 4.5-fold increase in arterial blood flow to
tumour which corresponds with the initial 4-fold increase in
the accumulation of MDP in tumour after co-injection with
DSM. Changes in liver tumour vascularity after DSM
embolisation have also been demonstrated in patients using
high-flow dynamic CT scanning (Civalleri et al., 1985). These
authors proposed that the arteriolar-capillary blockade
induced by DSM produces an increased arterial back
pressure that forcibly redistributes blood flow within the
liver. Alternatively local DSM embolisation may open up
arterio -arteriovenous shunts hitherto temporarily closed
(McCuskey, 1966). The intrahepatic shunting of blood may
be mediated via a temporary hypoxia induced by DSM
(Arfors et al., 1976) or reduction in the local washout of
adenosine (Lautt, 1985). As the DSM obstruct flow in one
channel these 'new' pathways allow the passage of co-injected
drugs to initially relatively ischaemic areas in the liver.
The selective targeting of a low molecular weight marker
to a hypovascular hepatic tumour after co-injection with
DSM can therefore be explained by an initial blockade of
hypervascular areas within the liver by microspheres with a
redistribution of flow to less vascular areas. The marker then
remains in tumour for longer than in the liver parenchyma
n-hg -t -t ow
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due to a combination of poor portal washout from tumour
and interruption ofthe tumour's main blood supply by DSM.
This effect will increase the local marker concentration and
encourage tumour uptake of marker.
Concomitant administration of DSM and cytotoxic drugs
which, unlike MDP, are actively retained by the liver may
result in even higher concentrations within liver tumours.
Furthermore, DSM could enhance the effects of internal
radiotherapy for liver metastases using regionally injected
yttrium-90-labelled microspheres (Burton et al., 1989).
Addition of the larger DSM may target the radioactive
microspheres to hypovascular tumours thereby sparing
normal hepatocytes. These results warrant further investiga-
tion into the clinical effects of DSM on the targeting of
cytotoxic agents to hypovascular liver tumours.
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